Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 2
2019 3
2020 4
2021 10
2022 11
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Development of a high throughput system to screen compounds that revert the activated hepatic stellate cells to a quiescent-like state.
Nakano Y, Saijou E, Itoh T, Tanaka M, Miyajima A, Kido T. Nakano Y, et al. Sci Rep. 2024 Apr 12;14(1):8536. doi: 10.1038/s41598-024-58989-6. Sci Rep. 2024. PMID: 38609454 Free PMC article.
Using aHSCs prepared from human induced pluripotent stem cells, we found that aHSCs were reverted to a quiescent-like state by a combination of chemical compounds that either inhibit or activate a signaling pathway, Lanifibranor, SB431542, Dorsomorphin, retinoic acid, palm …
Using aHSCs prepared from human induced pluripotent stem cells, we found that aHSCs were reverted to a quiescent-like state by a combination …
Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease.
Kamata S, Honda A, Kashiwagi N, Shimamura A, Yashiro S, Komori Y, Hosoda A, Akahoshi N, Ishii I. Kamata S, et al. Biomedicines. 2024 Mar 11;12(3):624. doi: 10.3390/biomedicines12030624. Biomedicines. 2024. PMID: 38540237 Free PMC article.
Using a time-resolved fluorescence resonance energy transfer assay, we analyzed the recruitment of four coactivator peptides (PGC1alpha, CBP, SRC1, and TRAP220) to human PPARalpha/delta/gamma-ligand-binding domains (LBDs) using eight PPAR dual/pan agonists (bezafibrate, fenofibri …
Using a time-resolved fluorescence resonance energy transfer assay, we analyzed the recruitment of four coactivator peptides (PGC1alpha, CBP …
Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.
Wang Y, Yi H, Sun W, Yu H, Tao W, Yu X, Jia D, Liu Y, Pandol SJ, Li L. Wang Y, et al. Drugs. 2024 Mar 13. doi: 10.1007/s40265-024-02015-6. Online ahead of print. Drugs. 2024. PMID: 38478331
Improvement of liver fibrosis stage ( 1) was observed with obeticholic acid 25 mg/day (OR 2.01, 95% CI 1.35-2.98), lanifibranor 1200 mg/day (OR 2.39, 95% CI 1.19-4.82) and silymarin (OR 4.54, 95% CI 1.18-17.43) in traditional meta-analysis. ...A prioritized selection of TZ …
Improvement of liver fibrosis stage ( 1) was observed with obeticholic acid 25 mg/day (OR 2.01, 95% CI 1.35-2.98), lanifibranor 1200 …
Pan PPAR agonist stimulation of induced MSCs produces extracellular vesicles with enhanced renoprotective effect for acute kidney injury.
Kim H, Lee SK, Hong S, Park TS, Kim J, Kim S, Kim TM. Kim H, et al. Stem Cell Res Ther. 2024 Jan 2;15(1):9. doi: 10.1186/s13287-023-03577-0. Stem Cell Res Ther. 2024. PMID: 38167146 Free PMC article.
In this study, we investigated whether iMSCs stimulated with a pan-peroxisome proliferator-activated receptor (PPAR) agonist could enhance the therapeutic efficacy of EVs against AKI. METHODS: Human iMSCs were primed with or without lanifibranor, a PPAR agonist for 24 h, a …
In this study, we investigated whether iMSCs stimulated with a pan-peroxisome proliferator-activated receptor (PPAR) agonist could enhance t …
Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Hansen HH, Pors S, Andersen MW, Vyberg M, Nøhr-Meldgaard J, Nielsen MH, Oró D, Madsen MR, Lewinska M, Møllerhøj MB, Madsen AN, Feigh M. Hansen HH, et al. Sci Rep. 2023 Dec 27;13(1):23056. doi: 10.1038/s41598-023-50328-5. Sci Rep. 2023. PMID: 38155202 Free PMC article.
Here, we profiled monotherapy with semaglutide (glucagon-like-receptor-1 receptor agonist) and lanifibranor (pan-peroxisome proliferator-activated receptor agonist) in a diet-induced obese (DIO) mouse model of NASH-HCC. ...Consistent with clinical trial outcomes in NASH pa …
Here, we profiled monotherapy with semaglutide (glucagon-like-receptor-1 receptor agonist) and lanifibranor (pan-peroxisome prolifera …
Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review.
Tidwell J, Balassiano N, Shaikh A, Nassar M. Tidwell J, et al. World J Hepatol. 2023 Aug 27;15(8):1001-1012. doi: 10.4254/wjh.v15.i8.1001. World J Hepatol. 2023. PMID: 37701920 Free PMC article.
Different investigational products were assessed: The most common cyclophilin inhibitor was NV556; FGF agonists and analogs was Efruxifermin; pan-PPAR agonists was Lanifibranor; and dual-PPAR agonists was Saroglitazar. All classes were found to be statistically efficacious …
Different investigational products were assessed: The most common cyclophilin inhibitor was NV556; FGF agonists and analogs was Efruxifermin …
Functional and Structural Insights into the Human PPARalpha/delta/gamma Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor.
Kamata S, Honda A, Ishikawa R, Akahane M, Fujita A, Kaneko C, Miyawaki S, Habu Y, Shiiyama Y, Uchii K, Machida Y, Oyama T, Ishii I. Kamata S, et al. Antioxidants (Basel). 2023 Jul 29;12(8):1523. doi: 10.3390/antiox12081523. Antioxidants (Basel). 2023. PMID: 37627519 Free PMC article.
Seven high-resolution cocrystal structures (namely, those of the PPARalpha/delta/gamma-ligand-binding domain (LBD)-lanifibranor, PPARalpha/delta/gamma-LBD-seladelpar, and PPARalpha-LBD-elafibranor) were obtained through X-ray diffraction analyses, six of which represent th …
Seven high-resolution cocrystal structures (namely, those of the PPARalpha/delta/gamma-ligand-binding domain (LBD)-lanifibranor, PPAR …
Targeting lipid-sensing nuclear receptors PPAR (α, γ, β/δ): HTVS and molecular docking/dynamics analysis of pharmacological ligands as potential pan-PPAR agonists.
Mandal SK, Puri S, Kumar BK, Muzaffar-Ur-Rehman M, Sharma PK, Sankaranarayanan M, Deepa PR. Mandal SK, et al. Mol Divers. 2023 Jun 6. doi: 10.1007/s11030-023-10666-y. Online ahead of print. Mol Divers. 2023. PMID: 37280404
On the basis of ADMET analysis, the top ligand was subjected to MD simulations, and compared with lanifibranor (reference PPAR pan-agonist). Comparatively, the top-scoring ligand showed better protein-ligand complex (PLC) stability with all the PPARs (alpha, gamma, beta/de …
On the basis of ADMET analysis, the top ligand was subjected to MD simulations, and compared with lanifibranor (reference PPAR pan-ag …
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
Tacke F, Puengel T, Loomba R, Friedman SL. Tacke F, et al. J Hepatol. 2023 Aug;79(2):552-566. doi: 10.1016/j.jhep.2023.03.038. Epub 2023 Apr 14. J Hepatol. 2023. PMID: 37061196 Review.
Targets for reducing the activation of inflammatory cascades include nuclear receptor agonists (e.g. resmetirom, lanifibranor, obeticholic acid), modulators of lipotoxicity (e.g. aramchol, acetyl-CoA carboxylase inhibitors) or modification of genetic variants (e.g. ...
Targets for reducing the activation of inflammatory cascades include nuclear receptor agonists (e.g. resmetirom, lanifibranor, obetic …
42 results